Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
ISSU
Penetrium Bioscience
★★

Penetrium Bioscience Announces 73.9 Billion Won Rights Offering… Dilution Inevitable but Funds Secured for Clinical Pipeline

  05/27/2026, 04:27 PM
MATR
Penetrium Bioscience
★

Penetrium Bioscience Announces Rights Offering of 8.5 Million Shares for Operational Funding, Raising Dilution Concerns

  05/27/2026, 03:50 PM
PERI
Penetrium Bioscience
★

Penetrium Bioscience: Q1 2026 Revenue Down, Net Loss Persists, Equity Boosted by FVOCI Gain

  05/15/2026, 03:42 PM
EXCH
Penetrium Bioscience
★

Phase 1 Trial Amendment for Pembrolizumab + Penetrium™ in Refractory/Recurrent Solid Tumors

  05/13/2026, 03:54 PM
ISSU
Penetrium Bioscience
★★

PenetriumBio Science Announces 73.8 Billion Won Rights Offering — Capital Raising Amid Financial Distress

  05/03/2026, 07:00 AM
MATR
Penetrium Bioscience
★★

Rights Offering Decision, Allocation Ratio of 0.155 Shares per Share

  05/03/2026, 07:00 AM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.